We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




High-Sensitivity Cardiac Troponin T Identifies Myocardial Injury with COVID-19

By LabMedica International staff writers
Posted on 01 Sep 2021
Cardiac troponin (cTn) is the preferred biomarker for the detection of myocardial injury (MI), which is defined when there is at least one cTn concentration above the 99th percentile upper-reference limit (URL) of a healthy reference cohort.

While pulmonary complications are frequent with COVID-19, studies suggest that myocardial injury is common, in particular among those with chronic cardiovascular conditions and more severe COVID-19 presentations, and that its presence and magnitude is associated with worse outcomes.

Cardiologist and a large team of medical scientists at the Mayo Clinic (Rochester, MN, USA) conducted a multicenter, retrospective, observational, US-based study of COVID-19 patients undergoing high-sensitivity cardiac troponin T (hs-cTnT). More...
The final study cohort included 367 COVID-19 patients in whom at least one hs-cTnT was obtained, amongst which 46% were identified to have myocardial injury based on hs-cTnT concentrations above the sex-specific 99th percentiles. The mean ± SD age of the cohort was 61 ±17 years and most patients presented through the Emergency Department (83%).

The hs-cTnT was measured with the Elecsys Troponin T Gen 5 STAT (Roche Diagnostics, Indianapolis, IN, USA). The lowest reportable clinical value is the <6 ng/L limit of quantification (LoQ). Sex-specific 99th percentiles URLs of 10 ng/L for women and 15 ng/L for men were used. Patients with suspected MI are evaluated using a 0/2 hour hs-cTnT protocol that uses sex-specific 99th percentile URLs to rule-in and rule-out myocardial injury and an absolute delta (serial change) of ≥10 ng/L to identify patients with acute injury. MI is diagnosed when there is objective evidence of myocardial ischemia.

The team reported that among 367 COVID-19 patients undergoing hs-cTnT, myocardial injury was identified in 46%. They had a higher risk for mortality (20% versus 12%), unadjusted hazard ratio (HR) of 4.44 and major adverse events (35% versus 11%). The hs-cTnT results were independent predictors of major adverse events. Most (95%) increases were due to myocardial injury, with 5% classified as type 1 or 2 myocardial infarction. A single hs-cTnT <6 ng/L identified 26% of patients without mortality, with a 94.9% (negative predictive value and 93.1% sensitivity for major adverse events in those presenting to the ED.

The authors concluded that myocardial injury is frequent and prognostic in COVID-19. While most hs-cTnT increases are modest and due to myocardial injury, they have important prognostic implications. A single hs-cTnT <6 ng/L at presentation may facilitate the identification of patients with a favorable prognosis. The study was published in the August 2021 issue of the journal Clinical Chemistry.

Related Links:
Mayo Clinic
Roche Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.